Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Microbix Biosystems Inc. T.MBX

Alternate Symbol(s):  MBXBF

Healthcare Biotechnology
Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab... see more

Recent & Breaking News (TSX:MBX)

Microbix Presenting at the 2024 Bloom Burton Conference

GlobeNewswire 13 days ago

Microbix Announces Annual and Special Meeting Voting Results

GlobeNewswire April 1, 2024

Microbix's Clot-Buster Drug Project Advances

GlobeNewswire March 14, 2024

Microbix Unveils Test Controls for Head and Neck Cancer

GlobeNewswire March 11, 2024

Microbix Announces Issuance of Stock Options

GlobeNewswire February 26, 2024

Microbix Reports Record Results for Q1 Fiscal 2024

GlobeNewswire February 14, 2024

Microbix Schedules Release of Results for Q1 Fiscal 2024 

GlobeNewswire February 7, 2024

Microbix Unveils Test Control for Gastric Ulcer Disease Pathogen

GlobeNewswire February 6, 2024

Microbix Achieves Further QAPs Sales Record

GlobeNewswire January 3, 2024

Microbix Reports Results for Q4 & Full-Year Fiscal 2023

GlobeNewswire December 21, 2023

Microbix & Seegene USA Jointly Enhancing Lab Test Accuracy

GlobeNewswire December 14, 2023

Microbix & BioGX Collaborate on real-time PCR Assays & Controls

GlobeNewswire December 7, 2023

Microbix Announces Initiation of Normal Course Issuer Bid

GlobeNewswire December 6, 2023

Microbix Presenting at Florida Capital Event Conference

GlobeNewswire November 17, 2023

Microbix Clot-Buster Drug Fully-Funded For Return to U.S. Market

GlobeNewswire November 16, 2023

Microbix & Ulisse Biomed Collaborate on HPV Controls & Assays

GlobeNewswire November 10, 2023

Microbix QAPs Supporting HPV Testing in Ireland

GlobeNewswire October 27, 2023

Microbix Presenting at Muskoka Capital Conference

GlobeNewswire September 29, 2023

Microbix Achieves New QAPs Sales Record

GlobeNewswire September 27, 2023

Microbix Honours the Passing of its Founder

GlobeNewswire September 13, 2023